Platinum (IV) prodrugs c, c, t-[PtCl 2 (NH 3) 2 (OH)(amlexanox)](MAP) and c, c, t-[PtCl 2 (NH
3) 2 (amlexanox) 2](DAP) were synthesized by reacting amlexanox with oxoplatin and …

Failure to engage apoptosis appears to be a leading mechanism of resistance to traditional
platinum drugs in patients with ovarian cancer. Therefore, an alternative strategy to induce …

Agents with multiple modes of tumor cell death can be effective chemotherapeutic drugs.
One example of a bimodal chemotherapeutic approach is an agent that can induce both …

Agents with multiple modes of tumor cell death can be effective chemotherapeutic drugs.
One example of a bimodal chemotherapeutic approach is an agent that can induce both …

The present study describes the synthesis and anticancer activity of novel octahedral PtIV
complexes with cyclohexyl functionalized ethylenediamine‐N, N′‐diacetate‐type ligands …

Platinum-based chemotherapeutics are widely used for cancer treatment but are frequently
limited because of dosage-dependent side effects and drug resistance. To attenuate these …

The current study unveils ONS-donor ligand based Pt (II) complexes with unusual anticancer
potency showing higher anticancer effect as compared to cisplatin. This series of Pt (II)(R …

A series of Pt (IV) prodrugs containing a microtubule inhibitor paclitaxel (PTX) were
synthesized and characterized and their antitumor activity was evaluated. Prodrugs 5–12 …

For the first time, two new mononuclear platinum (II) coordination compounds,[Pt
(L1)(DMSO) Cl](PtL1) and [Pt (L2)(DMSO) Cl](PtL2) with the 5-(ethoxymethyl)-8 …

Recently, palladium complexes have been extensively studied as cyclization of these
complexes by cyclometallation reactions increased their stability making them promising …